Albany, NY -- (SBWIRE) -- 12/13/2013 -- Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth

Pharma report - “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers are two orphan cancers of the gastrointestinal tract. They are often diagnosed at advanced, incurable stages due to a late onset of symptoms, but are also associated with low survival rates in the early stages of disease. Currently the primary treatment options are chemotherapy and surgery, which are used wherever possible. One monoclonal Antibody (mAb), Herceptin (trastuzumab) is marketed for use in suitable patients with advanced gastric or gastro-esophageal junction cancer. However, the late-stage pipelines for these indications include many promising mAb candidates which are anticipated to enter the market during the forecast period. Additionally, current market conditions are favorable for new mAbs, with high pricing patterns and weak impact from biosimilar exposure. As a result of this, GBI Research believes the global market has the potential to grow to a value of $766m by 2019.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/monoclonal-antibodies-market-in-gastric-and-esophageal-cancers-to-2019-crowded-late-stage-pipelines-and-favorable-market-conditions-encourage-robust-growth

Scope

A brief introduction to the two indications, including the disease’s pathogenesis, risk factors, diagnosis and treatment algorithms.
In-depth analysis of Herceptin, including analysis of its safety, efficacy, treatment patterns and strengths/weaknesses.
A comprehensive review of the pipeline for mAbs in gastric and esophageal cancer, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.
Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action.
Multi-scenario forecast data of the market to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Canada, Japan, Germany, the UK, France, Italy and Spain.
Discussion of the drivers and barriers for market growth.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/180975

Reasons to Buy

Understand the unmet need in the treatment of these cancers, the role of Herceptin and the areas of opportunity for other mAbs to enter the market.
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.
Observe the trends in clinical trial duration, size and molecule types across the phases of development and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for mAbs in gastric and esophageal cancers.
Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the market for mAbs in gastric and esophageal cancers.

Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Symptoms
2.1.1 Early Gastric Cancer
2.1.2 Early Esophageal Cancer
2.1.3 Advanced Gastric or Esophageal Cancer
2.2 Etiology
2.2.1 Esophageal Cancer
2.2.2 Gastric Cancer
2.3 Epidemiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Prognosis and Disease Staging
2.7 Treatment Options
2.7.1 Chemotherapy
2.7.2 Targeted Therapies
2.7.3 Treatment Guidelines
2.7.4 Resistance to Pharmacological Therapies
2.8 GBI Research Report Guidance

3 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Marketed Products
3.1 Herceptin (Trastuzumab) – Hoffman La Roche

4 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Developmental Pipeline
4.1 Gastric Cancer
4.1.1 Overall Pipeline
4.1.2 Molecular Targets
4.1.3 Clinical Trials
4.1.4 Conclusion
4.2 Esophageal Cancer
4.2.1 Overall Pipeline
4.2.2 Molecular Targets
4.2.3 Clinical Trials
4.2.4 Conclusion
4.3 Key Late-Stage Pipeline Products
4.3.1 AMG 102 (rilotumumab) – Amgen
4.3.2 IMC-1121B (Ramucirumab) – Eli Lilly and Company
4.3.3 Theraloc (Nimotuzumab) – YM Biosciences
4.3.4 MetMAb (Onartuzumab) - F. Hoffmann-La Roche
4.3.5 Perjeta (pertuzumab) - F. Hoffmann-La Roche
4.3.6 Kadcyla (ado-trastuzumab emtansine) - F. Hoffmann-La Roche
4.4 Conclusion

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/180975

5 Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019- Market Forecast to 2019
5.1 Gastric Cancer
5.1.1 Global
5.1.2 US
5.1.3 Canada
5.1.4 Europe
5.1.5 Japan
5.2 Esophageal Cancer
5.2.1 Global
5.2.2 US
5.2.3 Canada
5.2.4 Europe
5.2.5 Japan
5.3 Drivers and Barriers
5.3.1 Drivers
5.3.2 Barriers

6 Deals and Strategic Consolidations
6.1 Licensing Agreements
6.1.1 Gastric Cancer
6.1.2 Esophageal Cancer
6.2 Co-Development Agreements
6.2.1 Gastric Cancer
6.2.2 Esophageal Cancer

Latest Reports:

Echovirus Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/echovirus-diagnostics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019

An Enteric Cytopathic Human Orphan virus abbreviated as echovirus is an RNA virus that causes infections and diseases of gastrointestinal tract in the human body. Primarily, infants and young children are most susceptible to echovirus however it may also infect adults leading to various diseases such as acute febrile illness, respiratory diseases, rash, hand foot and mouth disease, myocarditis, encephalitis, neonatal sepsis and aseptic meningitis. There are no specific control measures or treatments for echovirus since its spread is contagious. Yet it can be prevented through implementing good hygiene practices and avoidance of shared utensils which may interrupt transmission of the virus. Rapid diagnosis of such virus is advantageous as it may avoid unnecessary treatment with antibiotics, reduces the length of hospitalization, and eventually reduces healthcare expenses.

The global echovirus diagnostic market is categorized based on:

Clinical applications
Molecular diagnostics
Immunoassays
Differential light scattering
Information technology
Liposomes
Flow cytometry
Chromatography
Gel micro-droplets
Diagnostic imaging
Monoclonal antibodies
Other

End user applications

Hospitals
Commercial/private laboratories
Physician offices
Public health labs

Globally, North America dominates the echovirus diagnostics market and is followed by Europe. Emerging countries of Asia, Middle East and Latin America are expected to drive the echovirus diagnostics market rapidly due to high rates of infections.

Some of the major factors driving the global echovirus diagnostics market include the increase in prevalence of echovirus infections in all ages due to its contagious nature, advances in molecular diagnostic technologies, bioterrorism and availability of immunosuppressive drugs in a wide range. Moreover, expansion of governmental health programs, especially in developing nations, may promote the rapid growth of echovirus diagnostics market in these regions.

Some of the major players contributing to the echovirus diagnostics market include Abbott Laboratories, Inc., Gen-Probe, Inc., Danaher Corporation, Becton Dickinson and Company, Novartis Diagnostics, Qiagen, F. Hoffmann-La Roche Ltd., Siemens Ltd., Ortho-Clinical Diagnostics, Thermo Fisher Scientific, Inc. and Wallac OY.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/toc/175284

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

North America
Asia Pacific
Europe
Rest of the World

This report provides comprehensive analysis of

Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

Endocrinology Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019: http://www.marketresearchreports.biz/analysis-details/endocrinology-drugs-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019

The human endocrine system comprises of a number of glands such as pituitary, thyroid, parathyroid, pancreas, pineal, thymus, parathyroid and gonads. These glands secrete hormones into the blood which are responsible for metabolism, growth, sexual development and other body functions. Endocrinology drugs are used to treat diseases related with insufficient hormones supply and dysfunctional glands. Various diseases related with endocrine system are Addison’s diseases, Cushing’s syndrome, Diabetes, Goiter, acromegaly, gigantism, osteomalacia, hypertension, hyperlipidemia, polycystic ovary syndrome (PCOS) and thyroiditis.

The global market for endocrinology drugs are divided into segments such as diabetes market, growth hormone market, acromegaly market and hypogonadism market. The market for diabetes is experiencing tremendous growth under the influence of increasing prevalence of diabetes worldwide. It is expected that by 2025, India and China will rank as the top most diabetic populated countries. Inception of new drug delivery for growth hormone and rising cases of cancers, end stage renal disease (ESRD) and increasing disposable income are driving the market for human growth hormone.

On the other hand off label uses of human growth hormone (HGH) for body building, anti-aging and in sports are posing a challenge to the society not only because it is illegal but also because use of HGH is associated with high risk and side effects. Hypogonadism market comprises of testosterone, estrogen and progesterone replacement therapy market. This segment will experience the growth due to increasing awareness about post menopausal hazards amongst women, awareness about testosterone amongst men.

Recent years have witnessed many advances in the treatment of endocrine diseases such as introduction of new drugs and novel drug delivery methods. Recently FDA approved endocrinology drugs include Invokana (canagliflozin) of Janssen Pharmaceuticas for the treatment of diabetes mellitus II, Osphena (ospemifene) of Shiongi for the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause. Others include Brisdelle (low-dose paroxetine mesylate), Nesina (alogliptin), Belviq (lorcaserin hydrochloride) and Cometriq (cabozantinib). The market is expected to face expiration of many patent including Sandostatin and Norditropin that will boost generic manufactures. The key players operating in this market are Abbott Laboratories, Novartis AG, Eli Lilly, Novo Nordisk, Roche, Facet Biotech Corporation, Alacer Corporation and Pfizer Inc.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/toc/175285

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include

North America
Asia Pacific
Europe
Rest of the World

This report provides comprehensive analysis of

Market growth drivers
Factors limiting market growth
Current market trends
Market structure
Market projections for upcoming years

This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.

About MarketResearchReports.Biz
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Blog: http://mrrfocuseconomics.blogspot.com/